FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review February 28, 2017October 19, 2019 by / Share This.....LinkedinTwitterFacebookGoogleEmailDownload PDF Related News: FDA accepts supplemental Biologics License…Roche’s Evrysdi (risdiplam) granted FDA priority…Roche’s Evrysdi (risdiplam) granted FDA priority…U.S. FDA grants priority review to Roche’s…FDA grants Priority Review to Roche’s Lunsumio for…FDA grants priority review to Roche’s bispecific…
